Adaptive Biotechnologies Corp represents a strong commitment to revolutionizing the diagnosis and treatment of diseases through its innovative biotechnology solutions. The company's corporate philosophy revolves around harnessing the power of the adaptive immune system to develop precise and accurate diagnostic tests and personalized therapeutics for various diseases. Adaptive Biotechnologies Corp strives to improve patient outcomes by combining cutting-edge technology, computational biology, and extensive research expertise. With an unwavering focus on advancing precision medicine, Adaptive Biotechnologies Corp aims to empower healthcare professionals with the tools they need to make informed decisions and improve the lives of patients.

Adaptive Biotechnologies Corp is primarily present in the United States.

Some significant milestones achieved by Adaptive Biotechnologies Corp include the successful completion of their initial public offering (IPO) in June 2019, raising approximately $345 million. They have also entered into collaborations and partnerships with notable organizations, such as Genentech, Microsoft, and Amgen, among others. Adaptive Biotechnologies Corp has made significant advancements in deciphering the adaptive immune system with their proprietary immune medicine platform. This has led to the development of groundbreaking diagnostic tools and therapeutics for various diseases, including cancer. They continue to expand their reach globally and are committed to advancing precision medicine through their innovative approach to harnessing the power of the immune system.

Adaptive Biotechnologies Corp is a healthcare company specializing in decoding the adaptive immune system to improve patient care. Founded in 2009 by Chad Robins and Harlan Robins, the company's innovative approach focuses on combining high-throughput sequencing with advanced bioinformatics to study the immune system and enable discoveries in various disease areas. Adaptive Bio has collaborations with leading pharmaceutical companies and research institutions worldwide. With its deep understanding of the adaptive immune system, the company aims to develop revolutionary diagnostics and therapies for diseases like cancer, autoimmune disorders, and infectious diseases. Adaptive Biotechnologies Corp is committed to transforming medicine through its cutting-edge technologies and unique insights into the immune system.

Adaptive Biotechnologies Corp faces competition from various companies in the market. Some notable competitors include Pacific Biosciences of California Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V. These companies also operate in the field of biotechnology, focusing on next-generation sequencing technologies and providing molecular diagnostic solutions. However, Adaptive Biotechnologies Corp distinguishes itself through its innovative and proprietary immune medicine platform, enabling the study of immune systems. By leveraging its unique technology, Adaptive Biotechnologies Corp maintains a competitive edge in the market.

Adaptive Biotechnologies Corp is primarily active in the biotechnology industry.

The business model of Adaptive Biotechnologies Corp revolves around leveraging their proprietary immune medicine platform to develop and commercialize innovative diagnostic tests and therapeutics for various diseases. By using high-throughput sequencing to study the adaptive immune system, the company aims to understand and decode the high complexity of immune responses. This enables them to identify and analyze the biomarkers related to various diseases, including cancer and infectious diseases, resulting in the development of targeted diagnostic tools and potential treatment options. With their focus on precision medicine, Adaptive Biotechnologies Corp aims to improve patient outcomes and contribute to the advancement of personalized healthcare.

لا يمكن حساب مضاعف الربحية للسهم لـAdaptive Biotechnologies في الوقت الحالي.

لا يمكن حالياً حساب معامل القيمة السوقية إلى العائدات لـ Adaptive Biotechnologies.

نقاط جودة AlleAktien لـ Adaptive Biotechnologies هي 3/10.

المتوقعة Adaptive Biotechnologies الإيرادات هي ٢٢٢٫٦٠ مليون. USD.

صافي الربح المتوقعة Adaptive Biotechnologies هو ؜-١٢٧٫٣٥ مليون. USD.

Adaptive Biotechnologies Corp is a biomedical company that focuses on the development of diagnostic tests and therapies to combat cancer and infectious diseases. The company was founded in 2009 and is headquartered in Seattle, Washington.

يوزع Adaptive Biotechnologies أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Adaptive Biotechnologies في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـAdaptive Biotechnologies هو US00650F1093.

رمز WKN لـ Adaptive Biotechnologies هو A2PLR5.

الرمز المُختصر لـ Adaptive Biotechnologies هو ADPT.

خلال آخر 12 شهراً، دفعت Adaptive Biotechnologies توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Adaptive Biotechnologies خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Adaptive Biotechnologies هي .

Adaptive Biotechnologies يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Adaptive Biotechnologies دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Adaptive Biotechnologies يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Adaptive Biotechnologies المُعلن عنها في ٢٧‏/٧‏/٢٠٢٥، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٧‏/٢٠٢٥.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٧‏/٧‏/٢٠٢٥.

في العام 2024، وزعت Adaptive Biotechnologies 0 USD كأرباح أسهم.

يتم توزيع أرباح Adaptive Biotechnologies بالعملة USD.